Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.50
-0.3%
$3.48
$2.45
$4.14
$277.76M0.25385,956 shs371,580 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$9.64
+2.6%
$7.64
$1.80
$20.63
$89.17M-0.792.11 million shs101,241 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$6.67
+8.5%
$4.50
$2.23
$17.41
$309.02M2.83880,740 shs1.41 million shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$4.44
-0.2%
$4.99
$3.50
$12.40
$274.21M1.42609,328 shs451,124 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%-0.28%-4.36%+37.65%+4.78%
CervoMed Inc. stock logo
CRVO
CervoMed
-1.05%-6.47%+31.47%+12.98%-22.51%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
+11.21%+1.65%+43.69%+96.49%-59.00%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
+6.21%-7.87%-13.76%+20.27%+11.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.0802 of 5 stars
3.30.00.00.02.02.51.3
CervoMed Inc. stock logo
CRVO
CervoMed
2.6131 of 5 stars
3.43.00.00.02.41.70.6
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.3023 of 5 stars
3.33.00.00.01.61.70.6
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.4744 of 5 stars
3.30.00.00.02.71.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0071.43% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.78
Moderate Buy$21.43122.29% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.64
Moderate Buy$30.40355.77% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.67
Moderate Buy$15.33245.35% Upside

Current Analyst Ratings Breakdown

Latest CRVO, FDMT, AVIR, and GLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$20.00 ➝ $16.00
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $15.00
8/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
8/1/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/29/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $27.00
7/29/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
7/25/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
7/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
7/3/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$4.59 per shareN/A
CervoMed Inc. stock logo
CRVO
CervoMed
$9.74M9.16N/AN/A$3.61 per share2.67
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K7,725.53N/AN/A$11.05 per share0.60
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$75.62M3.63N/AN/A$4.34 per share1.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%N/A
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.18N/AN/AN/A-594,375.81%-38.38%-35.02%8/14/2025 (Estimated)
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$72.70M$0.3612.33N/AN/A13.58%9.95%6.42%8/14/2025 (Estimated)

Latest CRVO, FDMT, AVIR, and GLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million
8/8/2025Q2 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million
8/7/2025Q2 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.46-$0.44+$0.02-$0.44N/AN/A
8/7/2025Q2 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.17
19.17
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
8.20
9.78
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
12.36
12.36
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
7.16
5.61

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7079.36 million64.99 millionOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
49.25 million5.62 millionNot Optionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.33 million41.88 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9061.76 million57.75 millionOptionable

Recent News About These Companies

Monte Rosa Therapeutics Insider Ups Holding During Year
Monte Rosa Therapeutics: Exercise Extreme Caution

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.50 -0.01 (-0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$3.56 +0.06 (+1.57%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$9.64 +0.24 (+2.55%)
Closing price 04:00 PM Eastern
Extended Trading
$9.60 -0.04 (-0.47%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$6.67 +0.52 (+8.46%)
Closing price 04:00 PM Eastern
Extended Trading
$6.57 -0.10 (-1.50%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$4.44 -0.01 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.48 +0.04 (+0.90%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.